Study #2021-0632
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
MD Anderson Study Status
Enrolling
Treatment Agent
INBRX-109, Placebo
Description
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Conventional Chondrosarcoma
Study phase:
Phase II
Physician name:
Anthony Conley
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.